Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor

Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, New Engl J Med, 355, 251, 10.1056/NEJMoa052256

Mark, 2010, Heart failure: epidemiology and prevention in India, Natl Med J India, 23, 283

Chaturvedi, 2016, Heart failure in India: the INDUS (INDia ukieri study) study, J Pract Cardiovasc Sci, 2, 28, 10.4103/2395-5414.182988

2015, A randomized trial of intensive versus standard blood-pressure control, New Engl J Med, 373, 2103, 10.1056/NEJMoa1511939

Cushman, 2016, SPRINT Study Research Group. SPRINT Trial Results: latest news in hypertension management, Hypertension, 67, 263, 10.1161/HYPERTENSIONAHA.115.06722

Fala, 2015, Entresto (sacubitril/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure, Am Health Drug Benefits, 8, 330

McMurray, 2013, Eur J Heart Fail, 15, 1062, 10.1093/eurjhf/hft052

Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128

Yancy, 2016, Circulation, 134, e282, 10.1161/CIR.0000000000000435

Yancy, 2017, ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Cardiac Fail

Jhund, 2016, The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan, Heart, 102, 1342, 10.1136/heartjnl-2014-306775

King, 2015, Neprilysin inhibition in heart failure with reduced ejection fraction: a clinical review, Pharmacother J Hum Pharmacol Drug Ther, 35, 823, 10.1002/phar.1629

U.S. Food and Drug Administration, 2017

Mangiafico, 2013, Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics, Eur Heart J, 34, 886, 10.1093/eurheartj/ehs262

von Lueder, 2015, Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy, Circ Heart Fail, 8, 71, 10.1161/CIRCHEARTFAILURE.114.001785

Wang, 2015, Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis, Int J Cardiol, 186, 104, 10.1016/j.ijcard.2015.03.116

Kobalava, 2016, Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LC) in patients with heart failure and reduced ejection fraction, Cardiovasc Ther, 34, 191, 10.1111/1755-5922.12183

McMurray, 2014, Angiotensin–neprilysin inhibition versus enalapril in heart failure, New Engl J Med, 371, 993, 10.1056/NEJMoa1409077

Hsiao, 2017, Evaluation of pharmacokinetic and pharmacodynamic drug–drug interaction of sacubitril/valsartan (LC) and sildenafil in patients with mild-to-moderate hypertension, Clin Pharmacol Ther, 1532

Jhund, 2015, Efficacy and safety of LC (sacubitril-valsartan) according to age: insights from PARADIGM-HF, Eur Heart J, 36, 2576, 10.1093/eurheartj/ehv330

Packer, 2014, Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure, Circulation, 131, 54, 10.1161/CIRCULATIONAHA.114.013748

Feldman, 2016, Valsartan/Sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations, JAMA, 315, 25, 10.1001/jama.2015.17632

Solomon, 2012, The angiotensin receptor neprilysin inhibitor LC in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial, Lancet, 380, 1387, 10.1016/S0140-6736(12)61227-6

Zile, 2011, Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction, Circulation, 124, 2491, 10.1161/CIRCULATIONAHA.110.011031

Kraigher-Krainer, 2014, Impaired systolic function by strain imaging in heart failure with preserved ejection fraction, J Am Coll Cardiol, 63, 447, 10.1016/j.jacc.2013.09.052

Solomon, 2017, Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction, JACC: Heart Fail, 5, 471

Williams, 2017, Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic HypertensionNovelty and significance, Hypertension, 69, 411, 10.1161/HYPERTENSIONAHA.116.08556

Packer, 2002, Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE), Circulation, 106, 920, 10.1161/01.CIR.0000029801.86489.50

Williams, 2002, Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session, J Am Coll Cardiol, 40, 1, 10.1016/S0735-1097(02)01982-4

Kostis, 2002, Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (OPERA) trial, Am J Hypert, 15, 193, 10.1016/S0895-7061(01)02048-9

Kostis, 2002, Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) study: design and the results of a landmark clinical trial in hypertension

Liao, 2003, Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects, Br J Clin Pharmacol, 56, 395, 10.1046/j.1365-2125.2003.01888.x

von Lueder, 2013, Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure, Circ Heart Fail, 10.1161/CIRCHEARTFAILURE.112.000289

Singh, 2015, Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond, Vasc Health Risk Manage, 11, 283

Wang, 2017, Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy, J Hypert, 35, 877, 10.1097/HJH.0000000000001219

Ito, 2015, Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, Hypert Res, 38, 269, 10.1038/hr.2015.1

Kristensen, 2016, Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction, Circ Heart Fail, 9, e002560, 10.1161/CIRCHEARTFAILURE.115.002560

Seferovic, 2017, Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial, Lancet Diabetes Endocrinol, 5, 333, 10.1016/S2213-8587(17)30087-6

Baranello, 2015, Amyloid-Beta protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s disease, Curr Alzheimer Res, 12, 32, 10.2174/1567205012666141218140953

Desai, 2017, Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial, JAMA Cardiol, 2, 79, 10.1001/jamacardio.2016.4733